Evaluation of Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Using EuroFlow Approaches

Background & Aims. Evaluation of the minimal residual disease (MRD) at different stages of chemotherapy is one of key prognostic factors and a factor of stratification of patients into risk groups in acute lymphoblastic leukemia (ALL). The MRD detection on Day 15 and at later stages is based on...

Full description

Bibliographic Details

Published in:	Клиническая онкогематология
Main Authors:	OA Beznos, LYu Grivtsova, AV Popa, MA Shervashidze, IN Serebryakova, OYu Baranova, EA Osmanov, NN Tupitsyn
Format:	Article
Language:	Russian
Published:	Practical Medicine Publishing House 2017-04-01
Subjects:	B-lineage acute lymphoblastic leukemia multicolor flow cytometry minimal residual disease
Online Access:	http://bloodjournal.ru/wp-content/uploads/2017/03/4.pdf